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CD157 signaling promotes 
survival of acute myeloid leukemia 
cells and modulates sensitivity 
to cytarabine through regulation 
of anti‑apoptotic Mcl‑1
Yuliya Yakymiv1,5, Stefania Augeri1,5, Cristiano Bracci1, Sara Marchisio1, Semra Aydin2, 
Stefano D’Ardia3, Massimo Massaia4, Enza Ferrero1, Erika Ortolan1* & Ada Funaro1*
CD157/BST‑1 (a member of the ADP‑ribosyl cyclase family) is expressed at variable levels in 97% 
of patients with acute myeloid leukemia (AML), and is currently under investigation as a target for 
antibody‑based immunotherapy. We used peripheral blood and bone marrow samples from patients 
with AML to analyse the impact of CD157‑directed antibodies in AML survival and in response to 
cytarabine (AraC) ex vivo. The study was extended to the U937, THP1 and OCI‑AML3 AML cell lines 
of which we engineered CD157‑low versions by shRNA knockdown. CD157‑targeting antibodies 
enhanced survival, decreased apoptosis and reduced AraC toxicity in AML blasts and cell lines. CD157 
signaling activated the PI3K/AKT/mTOR and MAPK/ERK pathways and increased expression of Mcl‑1 
and Bcl‑XL anti‑apoptotic proteins, while decreasing expression of Bax pro‑apoptotic protein, thus 
preventing Caspase‑3 activation. The primary CD157‑mediated anti‑apoptotic mechanism was Bak 
sequestration by Mcl‑1. Indeed, the Mcl‑1‑specific inhibitor S63845 restored apoptosis by disrupting 
the interaction of Mcl‑1 with Bim and Bak and significantly increased AraC toxicity in CD157‑high 
but not in CD157‑low AML cells. This study provides a new role for CD157 in AML cell survival, and 
indicates a potential role of CD157 as a predictive marker of response to therapies exploiting Mcl‑1 
pharmacological inhibition.
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Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous malignant disease characterized by 
abnormal proliferation of undifferentiated myeloid progenitors in the bone marrow (BM) and peripheral blood, 
impaired hematopoiesis and an aggressive clinical course. Intensive remission-inducing chemotherapy, followed 
by consolidation chemotherapy or allogeneic hematopoietic stem cell transplantation, in eligible patients with 
a high risk of relapse, still remains the standard therapeutic paradigm. However, mortality remains high, and 
most patients succumb to their disease in less than 5  years1,2. The dismal prognosis of AML is largely due to the 
acquisition of resistance to chemotherapy and leukemia relapse, which often overlap with deregulation of the 
apoptotic  machinery3. However, growing understanding of the molecular basis of AML have led to the introduc-
tion of new treatment options that exploit novel mechanisms of  action4. New drugs are rapidly being developed 
to expand the AML treatment landscape, with the promise of ultimately improving patient outcomes, especially 
in elderly patients and relapsed/refractory AML, the areas of greatest unmet  need5.
In AML, suppression of apoptosis by expression of anti-apoptotic members of the Bcl-2 family is one of 
the principal mechanisms underlying disease pathogenesis, resistance and relapse, making the anti-apoptotic 
members of the family attractive therapeutic  targets5,6. The basic idea is to kill leukemic cells by targeting the 
pro-survival members of the Bcl-2 family proteins with specific small molecule inhibitors that mimic the func-
tion of the BH3-only proteins, hence named BH3-mimetics. Currently, six BH3-mimetic drugs have entered 
clinical  trials7,8 whereas the Bcl-2 inhibitor, ABT-199/venetoclax has been approved for  therapy9,10. Although 
highly active, venetoclax monotherapy has shown limited efficacy in AML patients, and it proved to be more 
effective when used in combination with either hypomethylating agents or low-dose AraC for treatment-naive 
elderly  patients11. However, a non-negligible minority of patients are  refractory12 while the majority of patients 
who achieved remission, ultimately  relapse13. In a clinical trial on relapsed and refractory AML, sensitivity to 
venetoclax increased with increased Bcl-2 expression; in contrast, sensitivity decreased with increased expres-
sion of myeloid cell leukemia-1 (Mcl-1)14, a critical anti-apoptotic member of the Bcl-2 family and target of 
various inhibitors now being used in clinical trials, such as S63845. Therefore, on the one hand, AML treatment 
needs the rational design of effective drug combination strategies, on the other, we need to be able to identify 
patients most likely to benefit from therapies encompassing specific BH3-mimetic drugs, for example through 
the discovery of predictive biomarkers.
CD157/BST-1 glycoprotein was originally discovered as Mo5 myeloid  antigen15 and subsequently identi-
fied by RF3 monoclonal antibody as a cell membrane protein expressed in bone marrow stromal cells where it 
supports the growth of hematopoietic B cell  progenitors16, hence the name bone marrow stromal cell antigen 1 
(BST-1). CD157 is expressed by normal granulocytes, monocytes and more immature myeloid precursors. CD157 
interaction with the heparin binding domain of selected extracellular matrix (ECM) proteins (e.g., fibronectin, 
collagen type 1 and laminin) promotes intracellular signaling in leukocytes, and regulate their  adhesion17 and 
 transmigration18. As a GPI-anchored protein, CD157 must associate with β1 and β2-integrins for signaling to 
occur. CD157-directed agonistic antibodies are effective in mimicking the signaling effects of the myeloid cells/
ECM  interaction19–21.
We previously showed that in two non-hematological malignancies, ovarian  carcinoma22 and  mesothelioma23, 
CD157 overexpression correlated with tumor invasiveness, aggressiveness, and decreased sensitivity to platinum-
based  chemotherapy24, suggesting that CD157 is more than a bystander marker. In AML, CD157 is expressed 
both at diagnosis and relapse, with highest expression in myelomonocytic and monocytic AML subtypes (e.g., 
M4 and M5 subtypes, according to FAB classification). In addition, CD157 is also expressed in  CD34+CD38− leu-
kemia-initiating cells that contribute to AML  relapse25. Moreover, CD157 is currently under investigation as a 
target for antibody-based immunotherapy in AML (NCT02353143)26. However, the functional role of CD157 
in the biology of AML has never been explored. To address this issue, we used CD157-directed antibodies to 
reveal that CD157 activates pro-survival signals in AML and in response to treatment. The mechanistic basis of 
this pro-survival effect was investigated in detail using AML cell lines expressing high and low levels of CD157 
that confirmed the correlation between high CD157 expression, apoptosis inhibition and reduced sensitivity 
to chemotherapy. High CD157-expressing cell lines showed increased activation of the PI3K/AKT/mTOR and 
MAPK/ERK signaling pathways, converging on Mcl-1. Our study reveals a functional role of CD157 in pro-
survival signaling in AML cells and provides a rationale for the use of CD157 as a predictive marker of response 
to therapies exploiting Mcl-1 pharmacological inhibition.
Materials and methods
Patients. Peripheral blood (n = 11) or bone marrow (n = 8) samples from patients with newly diagnosed 
AML without any prior treatment, were obtained for ex vivo studies from the A.O.U Città della Salute e della 
Scienza (Torino, Italy) and from the A.O.S. Croce e Carle (Cuneo, Italy) hospitals. The average age of patients 
was 57 years (range 25–86), with five males and 14 females. Supplementary Table S1 lists the characteristics of 
the patients included in this study. The data were collected in accordance with the Declaration of Helsinki and 
good clinical practice guidelines. The study was approved by the local Institutional Review Board (Comitato 
Etico Interaziendale A.O.U. Città della Salute e della Scienza di Torino—A.O. Ordine Mauriziano—A.S.L. TO1 
and A.O.S. Croce e Carle, Cuneo, Italy). Full written informed consent was obtained from all patients involved in 
the study. Peripheral blood mononuclear cells and bone marrow mononuclear cells were separated by standard 
Ficoll-Hypaque density-gradient centrifugation. Mononuclear cells were cultured in DMEM medium supple-
mented with 20% fetal calf serum (FCS), 2 mM l-glutamine and 100-unit penicillin, 100 μg/ml streptomycin. 
According to the number of cells obtained from each sample, AML cells were used immediately for ex vivo 
experiments, or frozen in FCS with 20% DMSO.
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Cell lines. U937 and THP1 AML cell lines (from American Type Culture Collection, ATCC, Manassas, VA, 
USA) were grown in RPMI-1640 medium supplemented with 10% FCS; OCI-AML3 cells (kindly provided by 
G. Saglio, University of Torino, Italy) were cultured in DMEM medium supplemented with 20% FCS. Culture 
media were supplemented with 100-unit penicillin, 100 μg/ml streptomycin and 2 mM l-glutamine. Morphol-
ogy of cell lines was monitored routinely, and mycoplasma contamination was excluded using a PCR-based 
assay. DNA fingerprinting analysis using 16 different, highly polymorphic short tandem repeat loci (PowerPlex 
16 HS System, Promega) confirmed cell authenticity.
Antibodies and reagents. The SY11B5 anti-CD157 (IgG1) mouse monoclonal antibody (mAb) was pro-
duced in-house and affinity-purified on protein G. RF3 anti-CD157 (IgG1) mAb produced in mouse was pur-
chased from MBL (Voden-Medical, Meda, MB, Italy). The isotype control IgG1 produced in mouse (mIgG, clone 
MG1-45) was purchased from Biolegend (Aurogene, Roma, Italy). Purified murine IgG Fc fragments were from 
Jackson ImmunoResearch (West Grove, PA). Antibodies to phospho-mTOR Ser-2448 (D9C2, #5536), phos-
pho-p70S6K Thr-389 (108D2, #9234), phospho-AKT Ser-473 (D9E, #4060), phosphor-GSK-3β Ser-9 (D85E12, 
#5558), phosho-ERK1/2 Thr-202/Tyr-204 (D13.14.4E, #4370), phosho-S6 ribosomal protein Ser-235/236 (91B2, 
#4857), phosho-4E-BP1 Thr-37/46 (236B4, #2855), mTOR (L27D4, #4517), AKT (40D4, #2920), GSX3β (27C10, 
#9315) PARP-1 (46D11, #9532), Caspase-3 (D3R64, #14220), Caspase-9 (C9, #9508), Bcl-XL (54H6, #2764), 
Bcl-2 (D55G8, #4223), Bim (C34C5, #2933), Bax (D2E11, #5023), Bak (D4E4, #12105), Mcl-1 (D35A5, #5453), 
HRP-conjugated anti-mouse IgG1 (#7076) and HRP-conjugated anti-Rabbit IgG1 (#7074) were obtained from 
Cell Signaling Technology (Euroclone, Milan, Italy). Antibodies to β-actin (MAB-24008-HRP) and β-tubulin 
(MAB-80142-HRP) were purchased from Immunological Sciences (Roma, Italy). AraC was purchased from 
Sigma-Aldrich, S63845 and ABT-199/venetoclax inhibitors from Selleck Chemicals (Aurogene, Roma, Italy). 
Both ABT-199 and S63845 were dissolved in DMSO. Fibronectin from human plasma, Fibrinogen and Collagen 
type I were from Sigma-Aldrich (Milano, Italy).
Immunofluorescence staining and flow cytometry analysis. CD157 surface expression on AML 
samples and cell lines was assessed by flow cytometry (BD FACS Canto, BD Biosciences) by staining cells 
(3 ×  105/sample) with a PE-labeled mAb against CD157 (clone SY11B5, Invitrogen, Milan, Italy) for 20 min at 
4 °C. Leukemic blasts were analyzed by multiparametric flow cytometry and gated based on CD45 expression 
(anti-CD45-APC/H7, BD Biosciences) and side scatter  (CD45dim and  SSClow). To further characterize blast sub-
populations the following antibodies were used: CD33-FITC, CD34-PE/Cy7, CD64-PE, CD117-PE, CD123-PE/
Cy7, HLA-DR-FITC (Biolegend). Specifically, this back-gating allowed us to identify leukemic myeloid blasts 
 (CD33dim, CD64−, CD117+, CD123+, HLA-DR+) and leukemic monocytic populations (CD33+, CD64++, 
 CD117low/neg, CD123+, HLA-DR++). Data were analyzed using FlowJo software Version 10.6 (BD Biosciences). 
CD157 relative Mean Fluorescence Intensity (MFI) was normalized to the MFI of lymphocytes, which are 
CD157 negative. CD157 MFI ratio was calculated according to the formula: (MFI of CD157 in blasts − MFI of 
CD157 in lymphocytes)/MFI of CD157 in lymphocytes.
CD157 gene knockdown by shRNA. CD157 expression in U937, THP1 and OCI-AML3 cell lines was 
silenced by lentiviral delivery of pLV-puro (Biosettia, San Diego, CA) encoding the BST-1 short-harpin RNA 
(shRNA) (target sequences: 5′-GAG TCA GAC TGC TTG TAT A-3′ (shCD157#1) and 5′-CCT GAG CGA TGT TCT 
GTA T-3′ (shCD157#2) or a scrambled negative control (scrambled sequence: 5′-TTC TCC GAA CGT GTC ACG 
TT-3′), as previously  described24.
RNA extraction and RT‑PCR. Total RNA was extracted from transduced AML cell lines using TRI rea-
gent (Sigma-Aldrich), and quality and quantity checked with NanoDrop (ND-100, Thermo Fisher Scientific, 
Monza, Italy). 2 µg of RNA were reverse transcribed with the M-MLV Reverse Transcriptase (Invitrogen) and 
Oligo-dT primers (Sigma-Aldrich), as previously  described24. PCR products were analyzed by electrophoresis 
on 1% agarose gel stained with Midori Green Advance DNA Stain (NIPPON Genetics Europe, Düren, Austria).
Antibody‑mediated CD157 stimulation. In selected experiments, primary AML cells (5 ×  105/ml) or 
cell lines (4 ×  105/ml) were treated for 24 h (unless otherwise indicated) at 37 °C in standard culture medium or 
in serum-free conditions, as indicated, with affinity purified SY11B5 anti-CD157 mAb (10 µg/ml), or with an 
isotype-matched mIgG (10 µg/ml), as control. Then, cells were washed once in RPMI 1640 medium and pro-
cessed according to the indicated assay.
Flow cytometry analysis of apoptosis. Apoptosis was determined by flow cytometry measurement of 
phosphatidylserine exposure using Annexin V-FITC. Briefly, AML cells were treated with the indicated stimulus 
or drug for 24 h, washed once in RPMI 1640 medium, and then incubated with 100 µl of Annexin V binding 
buffer containing 2 µl of Annexin V-FITC and 2 µl of Propidium Iodide (PI) (Kit #IK-90314, Immunological 
Sciences) for 20 min at room temperature in the dark. Annexin V fluorescence was determined with a BD FACS 
Canto (BD Biosciences) flow cytometer and the membrane integrity of cells was simultaneously assessed by PI 
exclusion method. Flow cytometry analysis was performed by FlowJo software Version 10.6 (BD Bioscience). At 
least three independent experiments were performed with AML cell lines. Patient samples were chosen on the 
basis of availability of adequate cell number and experiments were performed once.
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PrestoBlue viability assay. Primary AML cells (6 ×  104/well) or AML cell lines (5 ×  104/well) were seeded 
in 96-well plates in 100 µl of culture medium supplemented with FCS and treated as indicated. Drugs at the 
indicated dilutions were added to each well. At each time point, 10 µl/well of PrestoBlue reagent (Thermo Fisher 
Scientific) was added for 1 h at 37 °C, then fluorescence was measured by using the Infinite M200 Pro Microplate 
Reader (Tecan Italia, Cernusco sul Naviglio, MI, Italy) with excitation/emission wavelengths set at 560/590 nm. 
Cell viability was determined by comparing the fluorescence values before and after treatment and normalizing 
the data to controls. Half-maximal effective concentration  (EC50) values were calculated by non-linear regression 
algorithms and a four-parameter logistic model with log-transformed data using GraphPad Prism 7 software.
Western blot analysis and immunoprecipitation. Cells were washed and harvested in ice-cold phos-
phate-buffered saline and subsequently lysed in extraction buffer (50 mM Tris HCl pH7.4, 150 mM NaCl, 1% 
Triton-X 100, 0.5% Sodium Deoxycholate, 1 mM EDTA, 1 mM EGTA, 10 mM NaF, 0.1% SDS) supplemented 
with 1 mM  Na3VO4 and protease inhibitor cocktail. Protein concentration was determined using the Bradford 
assay (BioRad Laboratories, Segrate, MI, Italy). Equal amounts of proteins were separated by an Any-kD Cri-
tereon TGX Stain-free PreCast gel (BioRad) and transferred to nitrocellulose membranes (Trans-blot Turbo 
Transfer pack, BioRad). After blocking with 2% BSA for 1 h, membranes were cut to minimize antibody use 
and each strip was separately probed with the indicated primary antibody, followed by the appropriate HRP-
conjugated secondary antibody. Immunoreactive proteins were detected using enhanced chemiluminescence, 
images were captured with a ChemiDoc XRS + System. Band densitometry measurements were performed with 
Image Lab Software (BioRad).
For immunoprecipitation, after the indicated treatments, cell extracts were obtained using lysis buffer (con-
taining 50 mM Tris HCl pH7.4, 150 mM NaCl, 1% NP-40, 0.5% Sodium Deoxycholate) supplemented with 5 mM 
EDTA, 10 mM NaF, 1 mM  Na3VO4, 1 mM DTT and protease inhibitor cocktail. An equivalent of 1 mg/sample 
of protein extracts was incubated overnight at 4 °C with anti-Mcl-1 (D2W9E, #94296) or anti-Bim (C34C5, 
#2933) antibodies (Cell Signaling, Euroclone, Milan, Italy), and subjected to immunoprecipitation with 20 µl of 
anti-rabbit IgG-coated Sepharose beads (Cell Signaling) for 3 h at 4 °C. Proteins were eluted by boiling samples 
for 5 min at 95 °C with 3× SDS reducing sample buffer and then analyzed by Western blotting. Equal amounts 
(20 µg) of lysate was prepared as described above, and used as whole-cell lysate control.
Statistical analysis. Unless otherwise indicated, results of in  vitro experiments are expressed as 
means ± SEM of at least three independent experiments. Comparisons among multiple groups were performed 
with both one-way and two-way ANOVA models. Differences between two groups were analyzed using unpaired 
two-tailed Student’s t-test. When the data were not normally distributed, the comparison of variables was per-
formed with a Wilcoxon signed rank test for paired data or with a Mann–Whitney test for unpaired data. All 
statistical analyses were performed using GraphPad Prism 7.0 (GraphPad Software, San Diego, CA). For all 
analyses, p values < 0.05 were considered statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 
versus control, and ns for not significant).
Results
CD157 promotes primary AML cell survival ex vivo. Primary AML cells maintained ex vivo in stand-
ard culture conditions spontaneously undergo apoptosis, caused by absence of soluble mediators and lack of 
interactions between leukemic cells and both cellular and extracellular stromal  components27,28. To explore the 
potential role of CD157 signaling in AML cell survival in vitro, we used BM and peripheral blood samples from 
Figure 1.  CD157 modulates viability in primary AML cells. Mononuclear cells from AML patients were 
maintained ex vivo for 24 h under standard culture conditions (untreated) or treated with (A, B) SY11B5 
anti-CD157 mAb or (B) control mIgG, then were subjected to AnnexinV/PI staining and flow cytometry 
analysis. Each dot represents a single patient. p < 0.0001 and p = 0.02, Wilcoxon’s signed-rank test. (C) Flow 
cytometry analysis of a bone marrow sample from a representative AML patient. Density plots show the 
distribution of each population composing the mononuclear cell fraction (X axis = FSC, Y axis = SSC) at time 
zero (T0), after 24 h in standard medium (untreated, top panels), with mIgG (bottom left panel) or SY11B5 
anti-CD157 mAb (bottom right panel). Lymphocytes  (FSClow/SSClow) and blasts  (FSCdim/SSCdim) were gated 
according to morphological parameters. Percentage indicates the frequency of each population compared 
to total acquired events. (D) Pro-survival effect of increasing concentrations of SY11B5 anti-CD157 mAb or 
mIgG at 24 h in primary AML cells from a representative patient. Black bar represents the percentage of viable 
untreated cells. (E) Pro-survival effect of SY11B5 anti-CD157 mAb compared with mIgG. The percentage of 
live cells at each time point compared to time zero is shown. The graph is a representative PrestoBlue assay 
performed in quadruplicate. **p < 0.01, ***p < 0.001, ****p < 0.0001, two-way ANOVA with Sidak’s multiple 
comparison test. Western blot analysis of phosphorylation levels of the indicated proteins of (F) PI3K/
AKT/mTOR pathway and (G) Bcl-2 apoptotic pathway, following CD157 stimulation for 24 h with SY11B5 
anti-CD157 (10 µg/ml) mAb or mIgG (10 µg/ml), used as isotype-matched control. β-Actin was used as loading 
control. A representative Western blot is shown out of four patients analysed with similar results. Samples 
analysed in panel F and G derive from the same experiment and were processed in parallel. Uncropped blot 
image is provided in Supplementary Fig. S8. (H) AML samples were treated for 24 h with vehicle or AraC 
(10 µM) in the presence of anti-CD157 mAb or mIgG (both at 10 µg/ml). The percentage of apoptotic cells 
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19 newly-diagnosed AML patients (Supplementary Table S1) showing variable levels of CD157 expression (Sup-
plementary Fig. S1).
To test for CD157-driven effects on AML cell viability, cells were maintained for 24 h in DMEM culture 
medium with 20% FCS in the presence of SY11B5 agonistic anti-CD157 mAb, or without (untreated control). 
Then, cell apoptosis was quantified by Annexin V/PI double staining and flow cytometry analysis. After 24 h of 
ex vivo culture, AML cell apoptosis ranged from 15.6 to 92.5%. However, for every sample tested, the percentage 
of apoptotic cells (e.g., Annexin V+) decreased after CD157 mAb treatment with respect to untreated controls 
(Fig. 1A). In contrast, treatment with an isotype-matched control mAb (mIgG) had no protective effect against 
apoptosis (Fig. 1B and Supplementary Fig. S2A). Five AML cell samples showing > 50% apoptosis ex vivo had 
low expression of CD157; however, the correlation between CD157 expression and ex vivo survival was not 
statistically significant, at least in the small number of samples analysed (Supplementary Fig. S2B).
To determine whether the pro-survival effect mediated by CD157 was specific to leukemic blasts, flow cytom-
etry analysis was carried out on cell subsets identified through forward scatter (FSC) and side scatter (SSC) 
parameters at baseline (T0) and following 24 h ex vivo culture in the presence or absence of anti-CD157 mAb 
(or control mIgG) (Fig. 1C). After 24 h, the percentage of viable blasts remained almost unchanged (42.6% vs 
40.1%) in the CD157 antibody-treated sample. However, in untreated and mIgG-treated samples, the percent-
age of viable blasts was notably reduced (42.6% vs 27.2% and 29.6%, respectively). In addition, we observed that 
CD157-mediated survival was dose-dependent (Fig. 1D) and extended in time to at least 72 h (Fig. 1E). These 
results indicate that CD157 contributed to leukemic blast survival.
CD157 regulates intracellular signal transduction and apoptosis. To decipher the molecular 
mechanisms through which CD157 promoted AML blast survival, we analyzed the intracellular signals elicited 
by CD157 mAb targeting in AML cells. We focused on PI3K/AKT/mTOR and mitogen-activated protein kinase 
(MAPK)/extracellular signal kinase (ERK) signal transduction pathways, known to be activated through CD157 
targeting in  monocytes20 and also frequently deregulated in  AML29,30.
Antibody targeting of CD157 expressed in primary leukemic cells for 24 h induced phosphorylation, as 
visualized by Western blot analysis, of: (1) mTOR and its downstream substrates p70S6K, pS6 ribosomal protein 
and 4E-BP1; (2) ERK and (3) AKT at its Ser-473, leading to (4) Ser-9 inactivating phosphorylation of Glycogen 
Synthase Kinase 3β (GSK-3β) (Fig. 1F). GSK-3β is a major AKT target, implicated in several cellular processes, 
including the regulation of cell  death31, and GSK-3β was previously found to be associated with poor survival 
outcome in AML  patients32. Next, to gather evidence that CD157 stimulation could modulate apoptosis, AML 
cells were treated with anti-CD157 mAb or mIgG as before, and analysed by Western blot for expression of 
proteins belonging to the Bcl-2-family. Although Bcl-2 expression was marginally affected, the anti-apoptotic 
proteins Mcl-1 and Bcl-XL were strongly upregulated while the pro-apoptotic protein Bax was clearly down-
regulated following CD157 antibody-binding. Moreover, CD157 stimulation reduced the proteolytic cleavage 
of Caspase-3 and its substrate PARP-1, considered to be hallmarks of apoptosis (Fig. 1G). Collectively, these 
results highlighted that by activating the PI3K/AKT/mTOR and MAPK signaling pathways, CD157-mediated 
intracellular signals can contrast spontaneous apoptosis in primary AML cells ex vivo and promote cell survival.
CD157 modulates AraC‑mediated apoptosis in primary AML blasts. Next, we investigated if 
CD157 signaling could protect AML blasts from apoptosis induced by therapeutic drugs, such as AraC, a main-
stay of AML treatment, thus potentially interfering with the efficacy of chemotherapy. To address this issue, 
eight bone marrow samples were treated ex  vivo with anti-CD157 mAb or with control mIgG immediately 
before addition of 10 µM AraC. Cell apoptosis was determined after 24 h. Ligation of CD157 by SY11B5 mAb 
significantly reduced the number of apoptotic cells in the AML samples, compared to the corresponding con-
trols treated with mIgG (Fig. 1H), indicating that CD157 signaling can interfere with AraC-induced apoptosis 
in primary AML cells.
CD157 prevents apoptosis induced by nutrient deprivation in AML cell lines. To combine the 
antibody-mediated approach with genetic manipulation of CD157 expression in AML cells, we extended our 
studies using U937, THP1 (both AML FAB M5 subtype) and OCI-AML3 (AML FAB M4 subtype) human AML 
cell lines which express variable levels of CD157 mRNA and protein (Supplementary Fig.  S3A,B,D) almost 
entirely consisting of the canonical CD157/BST-1 protein from the 9-exon transcript encoded by BST133 (Sup-
plementary Fig. S3C).
To evaluate their propensity for apoptosis under stress and the capacity of CD157 to rescue, the AML cell 
lines were placed in culture medium without FCS, a strategy known to induce activation of the mitochondrial 
apoptotic pathway in leukemia  cells34. After 24 h in serum-free medium, cell viability was measured and found 
to be significantly reduced in OCI-AML3 cells (Fig. 2A), whereas, U937 and THP1 cells were only marginally 
affected (Supplementary Fig. S4A). However, treatment with anti-CD157 mAb significantly increased OCI-AML3 
survival (Fig. 2A). Similar results were obtained by pretreating OCI-AML3 cells with saturating concentrations 
of murine IgG Fc fragments, thus excluding the potential interference of Fc receptor-mediated effects (Sup-
plementary Fig. S4B). By Western blot, CD157-stimulated OCI-AML3 cells showed increased phosphorylation 
of mTOR and AKT, and increased expression of Bcl-2, compared to the untreated control. Similar results were 
obtained with RF3 anti-CD157 mAb (Fig. 2B), which is known to bind to a different epitope.
To pinpoint the emerging role of CD157 in AML, we generated stable CD157 knockdown versions from the 
parental U937, THP1 and OCI-AML3 cell lines using lentiviral vectors expressing two shRNA (shCD157#1 
and shCD157#2) targeting CD157 or a scramble control sequence that conserved endogenous expression of 
CD157 (CD157high cells). CD157 expression in the genetically engineered cell lines was assessed by RT-PCR 
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Figure 2.  CD157 modulates cellular stress responses in AML cell lines. (A) OCI-AML3 cells were cultured overnight in 
the absence of FCS, then the SY11B5 anti-CD157 mAb or mIgG (both at 10 µg/ml) were added for 24 h. Cell viability was 
measured by AnnexinV/PI staining and flow cytometry analysis. Histograms show the effect of nutrient deprivation on cell 
viability expressed as fold change of viable cells compared to cells maintained in standard culture conditions, and are the 
mean ± SEM of six independent experiments performed in quadruplicate. *p < 0.05, ***p < 0.001, ns = not significant, one-way 
ANOVA with Tukey’s multiple comparison test. (B) OCI-AML3 were cultured overnight in serum-free medium then, SY11B5 
or RF3 mAbs to CD157 (10 µg/ml) were added for 24 h. Whole cell lysates were subjected to Western blotting and probed 
with the indicated antibodies. Blots were re-probed using antibodies against the total proteins. β-Actin was used as loading 
control. Numbers below blots indicate fold change in the expression of each protein relative to untreated control, normalized 
to the corresponding β-actin and total protein (mTOR and AKT). Uncropped images are provided in Supplementary Fig. S9 
(C) CD157-high or low OCI-AML3, THP1 and U937 cells were cultured in standard conditions or in serum-free medium for 
24 h, and then subjected to AnnexinV/PI staining and flow cytometry analysis. Results are expressed as fold change of viable 
cells normalized to CD157-high cells maintained in standard culture conditions and are the mean ± SEM of three experiments. 
*p < 0.05, **p < 0.01, one-way ANOVA with Tukey’s multiple comparison test. (D) CD157-high and CD157-low THP1 cells 
and (E) CD157-high and CD157-low U937 cells were maintained for 18 h in FCS-free culture medium, then were stimulated 
with FCS for 10 min or 2 h. Whole cell lysates were subjected to Western blotting and probed with the indicated antibodies. 
Blots were re-probed using antibodies against the total proteins. β-Actin was used as loading control. Numbers below blots 
indicate fold change in the expression of each protein relative to untreated CD157-high cells, normalized to the corresponding 
β-actin and total protein (AKT and GSK3β). Panels (D) and (E) show one Western blot representative of three independent 
experiments performed. Uncropped blot images are provided in Supplementary Fig. S9.
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(Supplementary Fig. S3A,B) and flow cytometry (Supplementary Fig. S3D). We selected the cell lines with low-
est CD157 expression (CD157-low) for further analysis to compare CD157high versus CD157low AML cells. 
Under standard culture conditions, the CD157-high and the CD157-low version of the AML cell lines showed 
similar proliferation ability (Supplementary Fig. S3E). However, when cultured in the absence of FCS for 24 h, 
the CD157-low cells showed significantly fewer live cells than the CD157-high cells, indicating that CD157 raises 
the apoptotic threshold in these leukemic cells (Fig. 2C).
We previously demonstrated that CD157-fibronectin interaction activates the PI3K/AKT/mTOR signaling 
 pathway17,18. To evaluate activation of this pathway, we selected the CD157-high and CD157-low version of 
THP1 and U937 cells (OCI-AML3 cells was excluded as the parental line has lower CD157 expression). After 
overnight starvation, cells were maintained in one of the following conditions: (1) standard culture, (2) without 
FCS, (3) with 10% FCS for 10 min and (4) with 10% FCS for 2 h. Cell extracts were then analysed by Western 
blot. In standard culture conditions, both CD157-high THP1 and U937 expressed higher Mcl-1 protein levels 
compared to their respective CD157-low counterparts. In the presence of FCS, CD157-high THP1 and U937 
showed more robust phosphorylation of AKT at Ser-493, GSK-3β kinase at Ser-9 and pS6 ribosomal protein at 
Ser-235/236 and increased the expression of Mcl-1 (especially after 10 min of exposure to FCS) with respect to 
their CD157-low versions (Fig. 2D,E). The same experiment was repeated in CD157-high and CD157-low THP1 
cells following treatment with purified fibronectin, fibrinogen or collagen type 1 that bind CD157, with similar 
results. Indeed, exposure to purified ECM proteins induced higher phosphorylation of AKT, GSK-3β kinase and 
pS6 ribosomal protein (especially after 10 min) and increased expression of Mcl-1 (after 2 h) in CD157-high than 
in CD157-low cells (Supplementary Fig. S5). Taken together, these results showed that stimulation of CD157 
by mAb binding or FCS/ECM protein stimulation significantly activated the PI3K/AKT/mTOR pathway while 
inactivating GSK-3β kinase, leading to upregulation of Mcl-1.
CD157 knockdown enhances AML cells sensitivity to AraC‑induced apoptosis. Having estab-
lished that CD157 rescues AML cell from apoptosis, we then analysed the impact of CD157 signaling in the 
response of AML cell lines to chemotherapy. First, cell viability was determined in THP1, U937 and OCI-AML3 
cells exposed to increasing concentrations of AraC for 24 h. In the experimental conditions adopted, U937 cells 
were sensitive to AraC treatment, while THP1 and OCI-AML3 cells were resistant (Fig. 3A). Hence, subsequent 
experiments were performed in U937 cells, further showing that U937/CD157-low were significantly more sen-
sitive to AraC toxicity than U937/CD157-high cells (Fig. 3B). The half-maximal effective concentration  (EC50) 
of AraC decreased from 4.8 µM in U937/CD157-high cells to 2.9 µM in U937/CD157-low cells (p = 0.0093). 
Moreover, following treatment with 10 µM AraC, the percentage of apoptotic U937/CD157-low cells was sig-
nificantly higher than that of U937/CD157-high cells (apoptotic cells = 66.0% ± 2.9 in CD157-low cells versus 
55.9% ± 3.1 in CD157-high cells; p < 0.01, n = 8) (Fig. 3C). Overall, these findings corroborate the results inferred 
from the experiments performed in patient-derived primary AML cells, and confirmed that CD157 signaling 
decreases the sensitivity of AML cells to AraC toxicity.
CD157 reduces the sensitivity of AML cells to AraC through the modulation of the intrinsic 
apoptotic pathway. Inhibition of apoptosis plays a central role in modulating malignant cell responses 
to anti-cancer therapy. Therefore, we investigated if CD157 signaling could decrease the sensitivity of U937 
cells to AraC by modulating apoptosis. Treatment of U937 cells with AraC is known to induce apoptosis by 
Mcl-1 degradation and Bax cleavage with generation of a pro-apoptotic fragment of 18-kDa35. By Western blot, 
U937/CD157-high cells showed higher constitutive levels of Mcl-1 than U937/CD157-low cells, which was only 
partly degraded after 24-h AraC treatment (Fig. 3D). Moreover, U937/CD157-high cells retained some degree of 
GSK-3β phosphorylation at Ser-9, which contributes to Mcl-1  stabilization36. Corroborating the reduced apop-
tosis observed in U937/CD157-high cells exposed to AraC, we found reduced activation of Bax pro-apoptotic 
effector and reduced cleavage of Caspase‐3 and PARP-1, compared to U937/CD157-low cells (Fig. 3D). These 
findings confirmed that signaling through CD157 modulates AML cell sensitivity to AraC by inhibiting apop-
tosis.
Figure 3.  CD157 knockdown increases AraC-induced cell death in U937 cells. (A) THP1 (black line), 
OCI-AML3 (dashed black line) or U937 (red line) cells were treated with increasing concentrations of AraC 
for 24 h to assess the sensitivity of each AML cell line to AraC. (B) The sensitivity of CD157-high (red line) 
versus CD157-low (blue line) U937 cells to AraC was compared by Presto Blue assays. Six replicates for each 
condition have been performed. Results are the mean ± SEM of four experiments. ****p < 0.0001, Student’s t-test. 
The  EC50 for U937 cells with high or low CD157 was calculated using the GraphPad software (see “Materials 
and methods”). (C) Representative dot plot (left) and histogram (right) of CD157-high and CD157-low U937 
cells treated with AraC for 24 h, obtained by flow cytometry analysis after AnnexinV/PI staining. Histograms 
show the mean ± SEM of eight independent experiments. **p < 0.01, two-way ANOVA with Sidak’s multiple 
comparison test. (D) U937/CD157-high and U937/CD157-low were treated with AraC for 24 h, then whole cell 
lysate was subjected to Western blotting. Numbers below blots indicate fold change in the expression of each 
protein relative to untreated CD157-high cells, normalized to the corresponding β-actin and full length protein 
(PARP, Bax and Caspase-3). β-Actin was used as loading control. Left panels: the levels of Mcl-1, pGSK-3β, 
cBax, cPARP, and cCaspase-3 were determined by densitometry analysis and are the mean of three experiments 
run in parallel. Uncropped blot is provided in Supplementary Fig. S10. Data are expressed as the mean ± SEM 
of band densities of western blots from three separate experiments. *p < 0.05, **p < 0.01, ****p < 0.0001, ns = not 
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To strengthen these observations, we assessed apoptosis in U937 treated with either ABT-199/venetoclax, a 
Bcl-2-specific inhibitor, or S63845, which specifically inhibits Mcl-1. Consistent with previous  observations37, 
U937 cells were resistant to ABT-199 (as were THP1 and OCI-AML3  cells6,38, data not shown), regardless of 
CD157 expression levels (Supplementary Fig. S6A). However, combined ABT-199 and AraC treatment signifi-
cantly increased apoptosis induced by AraC used as single drug, both in U937 with high or low CD157 (Sup-
plementary Fig. S6B). U937 cells were sensitive to S63845, although we found no correlation between sensitivity 
and Mcl-1 expression, as also observed in previous  studies39,40 nor CD157 expression (Fig. 4A). To assess the 
relationship between CD157-mediated anti-apoptotic effects and Mcl-1, U937 cells were treated with 20 nM 
S63845 for 24, 48 or 72 h and then analyzed by Western blot. After 24 h, Mcl-1 protein levels increased in both 
U937/CD157-high and U937/CD157-low cells (Fig. 4B), as S63845 is known to prolong Mcl-1 half-life39–41. 
However, accumulation of Mcl-1 was greater in CD157-high than in CD157-low cells. After 48–72 h, Mcl-1 was 
progressively degraded, while Caspase-3 and PARP-1 were cleaved, indicating activation of apoptosis. Cleavage 
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Figure 4.  CD157 promotes survival of leukemic blasts through Mcl-1 upregulation. (A) CD157-high (red 
line) or CD157-low (blue line) U937 cells were treated for 24 h with increasing concentrations of S63845, then 
cell viability was determined by Presto Blue assays. Data represents the percentage of live cells compared to 
control cells treated with vehicle and are the mean ± SEM of three experiments performed in six replicates. (B) 
Western blot analysis of PARP-1, Mcl-1 and cleaved Caspase-3 in CD157-high or CD157-low U937 cells treated 
with S63845 for 24, 48 or 72 h. β-Tubulin was used as loading control. Uncropped blot images are provided in 
Supplementary Fig. S11. (C) CD157-high or CD157-low U937 cells were treated for up to 72 h with S63845. Cell 
apoptosis was measured by flow cytometry analysis after AnnexinV/PI staining. Results are the mean ± SEM of 
three experiments. *p < 0.05, two-way ANOVA with Sidak’s multiple comparison test. (D) U937/CD157-high 
or U937/CD157-low cells were treated with S63845 for 24 h, then lysed and subjected to immunoprecipitation 
with anti-Mcl-1 or anti-Bim antibody, respectively. The interactions with the indicated proteins were analyzed 
by immunoblotting. β-Tubulin was used as loading control. One representative Western blot is shown (n = 3). 
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exposure to S63845, the percentage of cells undergoing apoptosis was significantly higher in CD157-high com-
pared to CD157-low U937 cells (Fig. 4C).
The anti-apoptotic Bcl-2 family proteins act by binding and inhibiting pro-apoptotic proteins, sensors of 
cellular stress (the BH3-only proteins) and effectors of apoptosis (Bax and Bak)42. To unravel the anti-apoptotic 
effect of CD157 expression in AML cells, using U937 cells with high or low CD157 we immunoprecipitated Mcl-1 
and found it was associated with Bim (Fig. 4D). In CD157-high cells, Mcl-1 also sequestered Bak. In contrast, 
the Mcl-1/Bak interaction was almost negligible in CD157-low cells. Treatment with 200 nM S63845 displaced 
Bim from Mcl-1 and drastically destabilized Mcl-1/Bak association. Reciprocal immunoprecipitation using a 
Bim antibody confirmed that in U937 cells Bim was mainly associated with Mcl-1, while it was only minimally 
associated with Bcl-2, regardless of the expression of CD157.
These data indicate that CD157 promotes survival of leukemic blasts through Mcl-1 upregulation, and suggest 
that sequestration of Bak by Mcl-1 might represent the primary CD157-mediated anti-apoptotic mechanism 
in AML cells.
Mcl‑1 inhibition improves therapeutic efficacy of AraC in CD157‑high AML cells. Overexpres-
sion of Mcl-1 has been implicated in resistance to both chemotherapy and to BH3-mimetics targeting Bcl-2 and 
Bcl-XL43, arousing considerable interest toward Mcl-1 as a therapeutic target in AML. Since Mcl-1 inhibitors are 
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Figure 5.  Mcl-1 inhibition improves therapeutic efficacy of AraC in CD157-high AML cells. (A) U937/CD157-
high or (B) U937/CD157-low cells were treated for 24 h with increasing concentrations of S63845 or AraC 
as single drugs or in combination, at constant ratio S63845:AraC = 1:100. Cell viability was measured by 
PrestoBlue assays and was expressed as fold change of viable cells compared to cells maintained in standard 
culture conditions. (C) Western blot analysis of U937/CD157-high or U937/CD157-low cells left untreated or 
treated for 24 h with S63845 or AraC as single agents or in combination. Uncropped blot images are provided 
in Supplementary Fig. S12. (D) The levels of Mcl-1 (left), and cleaved Caspase-3 (right) proteins determined by 
densitometry analysis was compared in CD157-high (white bars) or CD157-low (grey bars) U937 cells treated 
with AraC as single drug or in combination with S63845 for 24 h. Relative band intensities of the target proteins 
were measured by densitometric analysis. Results are means ± SEM of band densities of western blots from three 
separate experiments and are expressed as fold change over AraC-treated U937/CD157-high cells. *p < 0.05, 
***p < 0.001, ****p < 0.0001, ns = not significant, two-way ANOVA with Sidak’s multiple comparison test.
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efficacy of S63845 in combination with AraC in U937 cells with high or low CD157. Cells were treated for 24 h 
with increasing concentrations of AraC either as single agent or in combination with increasing concentrations 
of S63845, maintaining a constant ratio between the two drugs (S63845:AraC = 1:100). Cell viability was then 
determined by PrestoBlue assays, which measures metabolic activity. The results showed that in CD157-high, 
but not in CD157-low U937 cells, the addition of S63845 significantly enhanced AraC-induced cell death at all 
doses considered, with respect to AraC alone (Fig. 5A,B). Western blot analysis showed that S63845 enhanced 
the activation of Caspase-3 induced by AraC, especially in U937/CD157-high cells (Fig. 5C). Densitometric 
measurements of the amount of Mcl-1 and cleaved Caspase-3 confirmed that AraC-treated U937/CD157-high 
cells had higher levels of Mcl-1 (Fig. 5D, left) and lower levels of cleaved Caspase-3 (Fig. 5D, right) compared 
to CD157-low cells. This amply reflects the reduced sensitivity to AraC of U937/CD157-high cells. S63845 was 
able to significantly increase AraC-induced Caspase-3 cleavage in CD157-high but not in CD157-low U937 cells 
(Fig. 5D). Indeed, following combined treatment with S63845 and AraC for 24 h, the different sensitivity to AraC 
of U937/CD157-high compared to CD157-low cells was abrogated (Supplementary Fig. S7).
Discussion
In this study, we identified the biological function of CD157 in AML showing that CD157 favors survival and 
confers protection from stress or drug-induced apoptosis in primary AML blasts and AML cell lines. Two dif-
ferent experimental approaches support this notion. Firstly, antibody-directed binding of CD157 supported 
survival and reduced AraC-induced apoptosis in primary AML blasts ex vivo. Secondly, knockdown of CD157 
increased apoptosis in AML cell lines exposed to nutrient deprivation conditions, and increased their sensitivity 
to AraC toxicity. These findings are in line with previous studies from our laboratory demonstrating that high 
levels of CD157 expression can promote tumor cell survival and induce drug resistance in non-hematological 
tumors, namely epithelial ovarian  cancer22,45 and malignant pleural  mesothelioma23, eventually strengthening 
tumor aggressiveness. Further evidence derives from the study by Mirkowska et al.46 of the B-cell precursor acute 
lymphoblastic leukemia (BCP-ALL) surface proteome in which CD157 was identified as one of a restricted set 
of markers with significantly higher expression in BCP-ALL cells with respect to normal bone marrow B cell 
populations.
The correlation between high CD157 expression levels and the group of patients with “adverse prognosis” 
according to the European Leukemia Net (ELN) classification-201747 was reported in a small cohort of patients 
with  AML25. Although is a preliminary observation, this report supports the idea that CD157 expression is 
associated with aggressive disease progression in vivo.
In agreement with previous studies clearly delineating the ability of CD157 to act as a signaling  molecule20,21,33, 
our data showed that CD157 exerts its pro-survival effects in AML cells by transducing signals from external 
cues. Indeed, in primary AML cells, CD157 stimulation by antibody binding activated the PI3K/AKT/mTOR 
and MAPK/ERK pathways, while inactivating GSK3-β kinase thus leading to extended ex vivo survival and 
reduced sensitivity to AraC treatment. In addition, stronger phosphorylation of AKT, GSK-3β, mTOR and its 
downstream effectors was found in CD157-high versus CD157-low AML cell lines exposed to FCS (as source 
of ECM proteins) or to purified ECM proteins that bind  CD15717. PI3K/AKT/mTOR and MAPK/ERK intracel-
lular signaling pathways, as well as GSK3-β, regulate the expression and activity of apoptotic proteins ultimately 
ruling the balance between survival versus death of  cells48. In leukemic cells, aberrant activation of these intra-
cellular signals converge towards apoptosis escape, favoring tumor growth and eventually leading to resistance 
to  chemotherapy49. The results of this study unveiled that CD157 takes part to the cross-talk between the PI3K/
AKT/mTOR pathway and apoptosis, contributing to leukemic cell survival. In particular, CD157-mediated 
intracellular signals enhanced both Mcl-1 and Bcl-XL anti-apoptotic proteins; in contrast, they decreased Bax 
pro-apoptotic protein and prevented Caspase-3 activation, thus mitigating the apoptotic response in primary 
AML cells. Accordingly, knockdown of CD157 in U937 and THP1 cells reduced Mcl-1 and resulted in increased 
sensitivity to AraC toxicity in U937 cells. In U937 cells, the pro-apoptotic protein Bim was primarily bound to 
Mcl-1, while binding of Bim to Bcl-2 was barely detectable. In addition, in CD157-high U937 cells, Mcl-1 seques-
tered the pro-apoptotic effector protein Bak precluding the activation of the Bax/Bak-dependent mitochondrial 
 apoptosis50. Consistently, treatment with S63845, which binds with high affinity to the BH3-binding groove of 
Mcl-139,51, displaced Bim and Bak bound to Mcl-1 resulting in activation of the Bax/Bak-mediated  apoptosis52 
(Fig. 6). Used in combination with AraC, very low doses of S63845 were sufficient to significantly increase the 
therapeutic efficacy of AraC in CD157-high but not in CD157-low AML cells. Overall, these findings demon-
strated that CD157-driven intracellular signals upregulates Mcl-1, tilting the balance of leukemic cell homeostasis 
toward apoptosis evasion and raising their sensitivity threshold to AraC treatment, in vitro.
Remarkable clinical success with the Bcl-2 inhibitor venetoclax has revolutionized the treatment of hemato-
logical malignancies, including  AML6,53. Several landmark trials have demonstrated that venetoclax is effective in 
treating AML when combined with conventional cytotoxic  agents54. However, a significant minority of patients 
are refractory. In addition, the majority of patients that do achieve remission, eventually become resistant and 
 relapse55. The upregulation of Mcl-1 is often a primary mode of both acquired and intrinsic resistance to therapy 
with  venetoclax13,56. However, the baseline features that make patients less likely to respond to venetoclax-based 
regimens are not completely understood. Recently, it has been shown that AML with monocytic differentiation 
characteristics are resistant to venetoclax‐based regimens. Moreover, following prolonged administration of the 
drug, monocytic clones of leukemic cells emerge, which highly express Mcl‐1 and preferentially rely on Mcl-1 for 
 survival57. Intriguingly, differentiated monocytic cells, abundantly present in FAB M4 and M5 subtypes, express 
the highest CD157 levels compared to all other less differentiated AML  subtypes26. It is tempting to envision 
that high levels of CD157 expression could be a useful tool for the prospective identification of patients who are 
unlikely to respond to venetoclax, but most likely to benefit from Mcl-1 inhibition. It is reasonable to presume 
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that in addition to CD157 expression levels, a more refined strategy will include other molecular features such 
as genetic mutations. So far, no correlation has emerged between CD157 expression and specific mutations in a 
small cohort of molecularly heterogeneous AML patients  analyzed25. However, additional studies will require a 
much larger cohort of AML patients before conclusions can be drawn.
Conclusions
Increasing evidence supports the view that targeting apoptotic mechanisms is an effective strategy for treating 
 AML58. Finding optimal combinations of novel targeted agents, with minimal toxicity and maximal synergy, 
will be a critical task to deal with in the future to better address the dynamic complexity of AML and improve 
patient survival. Likewise, identifying predictive biomarkers for selection of patients most likely to benefit from 
specific anti-apoptotic combination regimens is essential for optimal design of therapies. Overall, the results 
of this study suggest that CD157 may be a promising candidate as a predictive marker of response to therapies 
exploiting Mcl-1 pharmacological inhibition.
Figure 6.  Schematic representation of CD157-mediated survival in AML cells. CD157 binding to fibronectin 
in AML cells promotes structural and functional interaction of CD157 with specific integrins. This activates 
intracellular signals leading to phosphorylation of AKT, mTOR and its downstream substrates p70S6K, pS6 
ribosomal protein, 4E-BP1, and ERK. In turn, phosphorylated AKT inactivates its major target GSK-3β, 
which loses its pro-apoptotic function and favors the stabilization of Mcl-1. The increased expression of 
Mcl-1 strengthens its ability to sequester Bim and Bak, thus precluding the Bak/Bax oligomerization at the 
mitochondrial outer membrane, which is required for cytochrome c release and is considered a key step in 
apoptosis. S63845 binds to the BH3-binding groove of Mcl-1 releasing Bim and Bak and enabling the activation 
of the Bax/Bak-dependent apoptotic pathway. This results in outer mitochondrial membrane permeabilization 
and release of cytochrome c into the cytosol leading to activation of the caspase cascade.
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Mcl-1 expression is essential for survival of human stem and progenitor cells and cardiac myocyte function-
ing, hinting to a relevant risk of severe on-target side effects in patients treated with Mcl-1 inhibitors. Clinical 
data gathered from ongoing phase I clinical trials (NCT02979366, NCT03672695) will provide better insight 
both into the therapeutic efficacy and side effects of Mcl-1  inhibitors40. An intriguing possibility to deliver Mcl-1 
inhibitory drugs preferentially (therefore, more safely) to leukemic cells could be to conjugate them to target-
directing antibodies. It is conceivable to envision that CD157-specific antibodies might be suitable candidates 
for this purpose.
Data availability
All data generated or analysed during this study are included in this manuscript and in Supporting information 
files. Part of data included in Supporting information are available at https:// doi. org/ 10. 5281/ Zenodo. 47763 08.
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